companies / kardigan-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-14 json
| total_raised | 554,000,000554.0M | ○ |
|---|---|---|
| founded | 2025 | |
| hq | South San Francisco, CA | |
| industry | unknown | |
| stage | series-b+ |
Kardigan develops cardiovascular drugs personalized to individual disease drivers, with a late-stage portfolio for genetic dilated cardiomyopathy, severe hypertension, and calcific aortic valve stenosis. It treats cardiovascular patients underserved by one-size-fits-all therapies. Kardigan stratifies patients by molecular profile.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-10-14 | series-b | 254,000,000254.0M | null | ○ |
Cloudflare, WordPress, Typekit, Adobe Fonts, Yoast SEO 27.4, reCAPTCHA, Google Analytics, Google Tag Manager, FitVids.JS, Font Awesome, jQuery Migrate, Cloudflare Bot Management
| fact | status | src |
|---|---|---|
| Series B, $254.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |